COVID-19 research
Gene: NRAS
Mice Deficient for N-ras: Impaired Antiviral Immune Response and T-cell Function PMID: 12670913
Knock out N-ras mice showed an increased sensitivity to influenza infection, especially when low doses of virus were used.
Effect of Human Activated NRAS on Replication of delNS1 H5N1 Influenza Virus in MDCK Cells
PMID: 21595878
Results: Huamn NRAS gene was activated by mutating in codon 61. Then the activation of NRAS was detected by western blot in MDCK cells. The delNS1 H5N1 influenza virus with deletion of NS1 eIF4GI binding domain was weak multiplication in MDCK cells. And the replication of delNS1 virus and expression of IFN-beta and IRF-3 were detected by Real-time PCR in MDCK cells infected with delNS1 virus. It was found that the delNS1 virus had a significant increase in MDCK cells when the NRAS was activated, and yet, expression of IRF-3 and IFN-beta were restrained.
Conclusions: The study demonstrated that activated NRAS played an important part for delNS1 virus replication in MDCK cells. Activated NRAS might be down-regulating the expression of antiviral cellular factors in delNS1 virus infected cells.Created: 10 Apr 2020, 12:06 p.m. | Last Modified: 10 Apr 2020, 12:06 p.m.
Panel Version: 0.81
Publications
agree with green geneCreated: 17 Sep 2019, 3:18 p.m. | Last Modified: 17 Sep 2019, 3:18 p.m.
Panel Version: 1.94
YES- this is covered on our targeted exomeCreated: 17 Sep 2019, 3:18 p.m. | Last Modified: 17 Sep 2019, 3:18 p.m.
Panel Version: 1.94
Certain somatic variants are linked to Ras-associated lymphoproliferative disorder but as there are several different linked phenotypes, caution required in reportingCreated: 29 Jun 2018, 3 p.m.
Mode of inheritance
Other
Comment on list classification: Associated with ?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic 614470 in OMIM and not in Gen2Phen. At least 1 SOMATIC variant identified in unrelated cases.Created: 9 May 2018, 10:26 a.m.
Comment on mode of inheritance: Somatic mosiacismCreated: 9 May 2018, 10:21 a.m.
Gene was flagged as requiring further clinical input from the Immunology Test Group, but no additional information was submitted to support the Green rating. In view of a lack of clear evidence the current recommendation is Amber.Created: 12 Nov 2019, 5:02 p.m. | Last Modified: 12 Nov 2019, 5:02 p.m.
Panel Version: 1.137
Noonan (plus malignancies in somatic variants): ?relevant phenotypeCreated: 26 Sep 2019, 3:57 p.m. | Last Modified: 26 Sep 2019, 3:57 p.m.
Panel Version: 1.130
This is a relevant phenotype but there is not enough evidence in the literature to date (PMID: 17517660 seems to report one person with NRAS and this phenotype) and there has been no further evidence in terms of unpublished cases other than a Green rating recommendation from the Immunology Specialist Test Group. To remain Amber unless further supporting evidence from the Test Group.Created: 17 Sep 2019, 5:21 p.m. | Last Modified: 17 Sep 2019, 5:21 p.m.
Panel Version: 1.101
Gene rating submitted by Kimberly Gilmour and Austen Worth on behalf of London North GLH for the GMS Immunology specialist test group. As discussed with the GMS Immunology Specialist Test Group during webex call 28th March 2019 and confirmed in follow up email 6th September the Specialist Test Group all agreed there is enough evidence to rate this gene Green.Created: 17 Sep 2019, 3:18 p.m. | Last Modified: 17 Sep 2019, 3:18 p.m.
Panel Version: 1.94
Gene rating submitted by Tracy Briggs, David Gokhale and Abigal Rousseau on behalf of North West GLH for the GMS Immunology specialist test group. As discussed with the GMS Immunology Specialist Test Group during webex call 28th March 2019 and confirmed in follow up email on 20th June the Specialist Test Group all agreed there is enough evidence to rate this gene Green.Created: 17 Sep 2019, 3:18 p.m. | Last Modified: 17 Sep 2019, 3:18 p.m.
Panel Version: 1.94
This gene was absent from the original PanelApp PID panel dataset (review April 2018). However it was listed in external expert immunodeficiency diagnostic gene list(s) GOSH or GRID. In this combined PID panel, this gene has been rated as AMBER and needs further curational review to assess pertinence prior to v1.Created: 20 Apr 2018, 12:25 p.m.
Original metadata downloaded from ESID Registry. ESID_Gene_original: N-Ras, PanelApp HGNC gene symbol check: NRAS, ESID classification: Main_category/ Sub_category/ PID_Diagnosis Diseases of immune dysregulation / Autoimmune lymphoproliferative syndrome (ALPS) / Ras associated lymphoproliferative disease (RALD)Created: 17 Apr 2018, 12:29 p.m.
Original metadata supplied by GRID. GRID Gene Symbol HGNC PanelApp check: NRAS, GRID_Gene_Symbol: NRAS, GRID_Transcript_ENS_Community submitted: ENST00000369535, GRID_Transcript_RefSeq: NM_002524.4, GRID_Transcript_ENS_used_on_Production: ENST00000369535Created: 17 Apr 2018, 12:12 p.m.
Mode of inheritance for gene: NRAS was changed from Unknown to Other
gene: NRAS was added gene: NRAS was added to Viral susceptibility. Sources: ESID Registry 20171117,North West GLH,GRID V2.0,NHS GMS,GOSH PID v.8.0,London North GLH,Expert Review Amber Mode of inheritance for gene: NRAS was set to Unknown Publications for gene: NRAS were set to 21079152; 5896945; 17517660; 29141318 Phenotypes for gene: NRAS were set to Ras associated lymphoproliferative disease (RALD); Autoimmune lymphoproliferative syndrome type IV; RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic 614470